LuciTir (Tirzepatide) 7.5mg/0.5mL Pre-filled Syringe

Product Overview
LuciTir contains the active ingredient Tirzepatide, a novel GLP-1/GIP dual receptor agonist designed as a convenient, once-weekly subcutaneous injection. It is indicated for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbid condition.

Tirzepatide works by mimicking two natural hormones (GIP and GLP-1) that regulate appetite, reduce hunger, and increase feelings of fullness. As a dual-agonist, it offers a more comprehensive approach to metabolic health compared to single-pathway GLP-1 agonists.

Key Features & Benefits
Once-Weekly Injection: One pre-filled syringe per week. No daily dosing required.

Significant Weight Loss: In the SURMOUNT-1 clinical trial, tirzepatide demonstrated dose-dependent weight loss. The 7.5mg dose achieved an average weight loss of 17.2% (38.2 lbs) over 72 weeks.

Dual-Action Mechanism: Targets both GIP and GLP-1 receptors for enhanced appetite control and blood sugar regulation.

Pre-filled Syringe: Ready to use. Easy to administer at home with minimal discomfort.

Flexible Administration: Can be injected into the abdomen, thigh, or upper arm. Rotate injection sites to reduce irritation.

Dosage and Administration
This product is LuciTir 7.5mg/0.5mL pre-filled syringe. The recommended titration schedule is as follows:

Starting Dose: 2.5mg once weekly for 4 weeks (initial adaptation)

Maintenance Dose (Level 1): 5mg once weekly for at least 4 weeks

Maintenance Dose (Level 2): 7.5mg once weekly for at least 4 weeks

Further Titration: Dose may be increased to 10mg, 12.5mg, or up to the maximum of 15mg based on individual tolerance and treatment response.

Important Administration Guidelines:

Inject once weekly on the same day each week.

If a dose is missed, it can be taken within 96 hours (4 days). If more than 96 hours have passed, skip the missed dose and resume the regular weekly schedule.

Do not take two doses within 3 days of each other.

Product Specifications
Item Details
Active Ingredient Tirzepatide 7.5mg per 0.5mL
Dosage Form Solution for injection
Pack Size 1 Pre-filled Syringe per box
Administration Subcutaneous injection once weekly
Prescription Status Rx Only (Requires a prescription)
Manufacturer Lucius Pharmaceuticals
Safety Information
Warnings and Precautions
Thyroid C-Cell Tumors: Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis: Discontinue use if severe abdominal pain is suspected.

Hypoglycemia: Concomitant use with insulin or sulfonylureas may increase the risk of hypoglycemia.

Pregnancy and Breastfeeding: May cause fetal harm. Discontinue if pregnancy is recognized.

Drug Interactions: Caution with oral contraceptives, NSAIDs, and diuretics.

Common Side Effects
The most common adverse reactions include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. These symptoms are usually mild to moderate and tend to improve over time.

Medical Disclaimer: This information is for product description purposes only and is not intended as medical advice. Always consult your healthcare provider before starting any prescription medication. This is a Rx Only product and requires a valid prescription.